New head of U.S. Medical Affairs, Oncology Business Group, at Eisai Inc.

New head of U.S. Medical Affairs, Oncology Business Group, at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd., has appointed Andree Amelsberg, M.D., MBA, as VP U.S. Medical Affairs, Oncology Business Group. He is responsible for the medical affairs strategy for the company’s oncology portfolio of both commercialized and investigational products in the United States. He is also overseeing Eisai Oncology’s medical directors, medical science liaisons (MSLs) and medical information and education teams in the U.S.

“We are delighted to welcome Dr. Amelsberg to Eisai, and look forward to collaborating with him as he leads our U.S. Oncology Medical Affairs team,” says Dr. Kirk Shepard, senior VP, chief medical officer and head of global medical affairs for the Oncology Business Group. “He joins Eisai amid exciting developments in both our early- and late-stage pipeline, as we seek to progress the development of multiple modalities aimed at addressing unmet needs across the cancer continuum.”

With more than 20 years of leadership in oncology medical affairs and drug development in the United States, Americas and Europe, Eisai executives say Dr. Amelsberg has extensive experience in establishing and leading highly effective medical affairs teams and clinical research departments in a broad range of therapeutic areas, including oncology, hematology, and non-oncology indications. He joins Eisai from HUTCHMED, where, as the senior VP of medical affairs, he led the organizational strategy on near-term launches and pipeline products.

Dr. Amelsberg has held executive-level positions in medical affairs at Janssen, Astellas, and Boehringer Ingelheim, where he contributed to multiple successful regulatory submissions, new product launches, and the lifecycle management of approved products.

“With their philosophy on the pursuit of human health care (hhc), Eisai shows an exciting commitment to patients, caregivers, and healthcare providers,” Dr. Amelsberg says. “Together with Eisai’s dedicated focus on a strong oncology portfolio, I am very much looking forward to contributing to the success of the organization in making novel drugs available to patients.” 

Dr. Amelsberg earned his M.D. degree from the University of Kiel in Germany, before attaining an MBA degree in global management in the United States. He is certified in internal medicine and medical oncology by the European Society for Medical Oncology (ESMO), and is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO), American Society for Hematology (ASH), European Hematology Association (EHA), and ESMO, among others.